Share this page: More
 

James M. Stevenson

James M. Stevenson 

Department Affiliation: Primary: Medicine (Division of Clinical Pharmacology; Secondary: Pharmacology and Molecular Sciences
Degree: Pharm.D., University of Michigan; M.S., University of Illinois at Chicago
Rank: Assistant Professor
Telephone Number: 248-396-9113
E-mail address: stevenson@jhmi.edu
School of Medicine Address: Osler 501, 600 N. Wolfe Street, Baltimore, MD 21287
Website:  Stevenson

 

Genetic influences on medication outcomes in psychiatry and cardiovascular medicine

Pharmacogenetics – the influence of genetic variability on medication outcomes – is an aspect of precision medicine. Genetic variability can affect efficacy, tolerability, and dose requirement. For several medications, the evidence for pharmacogenetic influence on outcomes is sufficient for routine use in clinical practice. My research program seeks to appropriately use these established associations to tailor treatment, and to identify new associations that could be used in the future. I have a particular interest in psychiatric medications and cardiovascular medications.   


Representative Publications:

  • Stevenson, J.M., Reilly, J.L., Patel, S., Harris, M.S., Prasad, K.M., Badner, J.A., Nimgaonkar, V., Keshavan, M.S., Sweeney, J.A., Bishop, J.R. Antipsychotic pharmacogenomics in first episode psychosis: a role for glutamate genes. Translational Psychiatry, 2016, Feb 23;6(2):e739. Pub Med Reference 
  • Empey, P.E., Stevenson, J.M., Tuteja, S., Weitzel, K.W., Angiolillo, D.J., Beitelshees, A.L., Coons, J.C., Duarte, J.D., Franchi, F., Jeng, L.J.B., Johnson, J.A., Kreutz, R.P., Limdi, N.A., Maloney, K.A., Owusu Obeng, A., Peterson, J.F., Petry, N., Pratt, V.M., Rollini, F., Scott, S.A., Skaar, T.C., Vesely, M.R., Stouffer, G.A., Wilke, R.A., Cavallari, L.H., Lee, C.R.; IGNITE Network. Multi-site investigation of strategies for the implementation of CYP2C19 genotype-guided antiplatelet therapy. Clin Pharmacol Ther., 2018, 104(4): 664-674. Pub Med Reference 
  • Beitelshees, A.L., Stevenson, J.M., El Rouby, N., Dillon, C., Empey, P.E., Fielstein, E.M., Johnson, J.A., Limdi, N.A., Ong, H.H., Franchi, F., Angiolillo, D.P., Peterson, J.F., Rosenman, M.B., Skaar, T.C., Tuteja, S., Cavallari, L.H.; IGNITE Pharmacogenetics Working Group. Evaluating the extent of reusability of CYP2C19 genotype among patients genotyped for anti platelet therapy selection. Genet Med., 2020, Nov 22(11):1898-1902. Pub Med Reference    

  • Stevenson, J.M., Alexander, G.C., Palamuttam, N., Mehta, H.B. Projected utility of pharmacogenomic testing among individuals hospitalized with COVID-19: A retrospective multicenter study in the United States. Clin Transl Sci., 2020 Oct 21. Pub Med Reference 
  • Stevenson, J.M., Bishop, J.R. Genetic determinants of selective serotonin reuptake inhibitor related sexual dysfunction. Pharmacogenomics, 2014, Nov;15(14):1791-1806. Pub Med Reference
  • Zhu, J., Klein-Fedyshin, M., Stevenson, J.M. Serotonin transporter gene polymorphisms and SSRI tolerability: review of pharmacogenetic evidence. Pharmacotherapy, 2017, Sept; 37(9):1089-1104. Pub Med Reference
  • Nutescu, E.A., Drozda, K., Galanter, W.L., Bress, A.P., Stevenson, J.M., Stamos, T.D., Desai, A.A., Gordeuk, V., Peace, D., Kadkol, S.S., Dodge, C., Saraf, S., Garofalo, J., Krishnan, J., Garcia, J.G., Cavallari, L.H. Feasibility of implementing a comprehensive warfarin pharmacogenetics service. Pharmacotherapy, 2013, 33(11):1156-1164. Pub Med Reference
  • Cavallari, L.H., Lee, C.R., Beitelshees, A.L., Cooper-DeHoff, R.M., Duarte, J.D., Voora, D., Kimmel, S.E., McDonough, C.W., Gong, Y., Dave, C.V., Pratt, V.M., Alestock, T.D., Anderson, R.D., Alsip, J., Ardati, A.K., Brott, B.C., Brown, L., Chumnumwat, S., Clare-Salzler, M.J., Coons, J.C., Denny, J.C., Dillon, C., Elsey, A.R., Hamadeh, I.S., Harada, S., Hillegass, W.B., Hines, L., Horenstein, R.B., Howell, L.A., Jeng, L.J.B., Kelemen, M.D., Lee, Y.M., Magvanjav, O., Montasser, M., Nelson, D.R., Nutescu, E.A., Nwaba, D.C., Pakyz, R.E., Palmer, K., Peterson, J.F., Pollin, T.I., Quinn, A.H., Robinson, S.W., Schub, J., Skaar, T.C., Smith, D.M., Sriramoju, V.B., Starostik, P., Stys, T.P., Stevenson, J.M., Varunok, N., Vesely, M.R., Wake, D.T., Weck, K.E., Weitzel, K.W., Wilke, R.A., Willig, J., Zhao, R.Y., Kreutz, R.P., Stouffer, G.A., Empey, P.E., Limdi, N.A., Shuldiner, A.R., Winterstein, A.G., Johnson, J.A.; IGNITE Network. Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. JACC Cardiovasc Interv., 2018, 11(2):181-191. Pub Med Reference
  • Lee, C.R., Thomas, C.D., Beitelshees, A.L., Tuteja, S., Empey, P.E., Lee, J.C., Limdi, N.A., Duarte, J.D., Skaar, T.C., Chen, Y., Cook, K.J., Coons, J.C., Dillon, C., Franchi, F., Giri, J., Gong, Y., Kreutz, R.P., McDonough, C.W., Stevenson, J.M., Weck, K.E., Angiolillo, D.J., Johnson, J.A., Stouffer, G.A., Cavallari, L.H.; IGNITE Network Pharmacogenetics Working Group. Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. Clin Pharmacol Ther., 2020, Sep 8. doi: 10.1002/cpt.2039. Pub Med Reference

 

 


Other graduate program in which Dr. Stevenson participates:  None